SPHERA FUNDS MANAGEMENT LTD
Q2 2024 Form 13-F
TEL AVIV
CIK 0001496201
· CRD 312614
· Exempt reporting adviser
Consolidated report · includes
2 managers
since Q4 2013
$733.2M Reported Value Total
SPHERA FUNDS MANAGEMENT LTD. reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
WWW.SPHERAFUND.COM
Source: Form ADV filed 2026-03-17
Reported value
$733.2M
Quarter over quarter
-8.4%
Holdings
110
Top-10 concentration
32.8%
Filing Structure
Reports holdings for
- Sphera Global Healthcare Management LP · File #028-15865 · since Q4 2013
- Sphera Global Healthcare GP Ltd · File #028-15864 · since Q4 2013
- Sphera Healthcare US Inc. (not a 13F filer in our records) · File #028-21415 · Q3 2021 – Q2 2022
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Oshrat Levi
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $733.2M |
| Positions | 110 |
| Change in reported value | +3.0% |
| New positions | 30 |
| Exited positions | 13 |
| Position turnover | 35.0% |
| Top-10 concentration | 32.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
100 | $707.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
97 | $766.5M |
|
Q1 2026 13F
Filed May 15, 2026
|
92 | $629.7M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
94 | $517.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
101 | $474.1M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
101 | $426.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
112 | $434.3M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
103 | $553.1M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
108 | $628.4M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
110 | $733.2M |
|
Q1 2024 13F
Filed May 15, 2024
|
93 | $711.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
89 | $621.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
75 | $549.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
76 | $640.4M |
|
Q1 2023 13F
Filed May 15, 2023
|
75 | $598.4M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
58 | $465.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
65 | $720.5M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
50 | $934.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
59 | $707.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
85 | $909.6M |
32 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TEVA C TEVA PHARMACEUTICAL INDS LTD | $53.1M | 7.24% |
| 2 | SMH P VANECK ETF TRUST | $39.1M | 5.33% |
| 3 | BBIO BRIDGEBIO PHARMA INC | $23.1M | 3.14% |
| 4 | SNY SANOFI | $21.8M | 2.97% |
| 5 | CYTK CYTOKINETICS INC | $20.9M | 2.84% |
| 6 | AMZN AMAZON COM INC | $19.6M | 2.67% |
| 7 | SNDX SYNDAX PHARMACEUTICALS INC | $16.9M | 2.3% |
| 8 | META META PLATFORMS INC | $16.9M | 2.3% |
| 9 | AZN ASTRAZENECA PLC | $14.8M | 2.02% |
| 10 | MSFT MICROSOFT CORP | $14.7M | 2.01% |
| 11 | NICE NICE LTD | $14.0M | 1.91% |
| 12 | SRPT SAREPTA THERAPEUTICS INC | $13.2M | 1.8% |
| 13 | AAPL APPLE INC | $13.0M | 1.77% |
| 14 | TEVA TEVA PHARMACEUTICAL INDS LTD | $12.8M | 1.75% |
| 15 | KURA KURA ONCOLOGY INC | $12.6M | 1.72% |
| 16 | RARE ULTRAGENYX PHARMACEUTICAL IN | $12.1M | 1.65% |
| 17 | LLY ELI LILLY & CO | $11.9M | 1.63% |
| 18 | PRAX PRAXIS PRECISION MEDICINES I | $11.7M | 1.6% |
| 19 | CLDX CELLDEX THERAPEUTICS INC NEW | $11.4M | 1.56% |
| 20 | NVO NOVO-NORDISK A S | $11.1M | 1.52% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.